Genetic Polymorphisms Implicated in Nonalcoholic Liver Disease or Selected Other Disorders Have No Influence on Drug‐Induced Liver Injury

Herbert L. Bonkovsky, Tyler Severson, Paola Nicoletti, Huiman Barnhart, Jose Serrano, Naga Chalasani, Robert J. Fontana, Paul B. Watkins, Victor Navarro, Andrew Stolz, Ann K. Daly, Guruparasad P. Aithal, Joseph Odin, the US DILIN Investigators – 6 June 2019 – With the application of genetic testing to contemporary medical diagnostics and practice, it has become apparent that the phenotypes of many disorders are modulated by host genetic factors.

Tumor Necrosis Factor Receptor–Associated Factor 6 Promotes Hepatocarcinogenesis by Interacting With Histone Deacetylase 3 to Enhance c‐Myc Gene Expression and Protein Stability

Hua Wu, Tian‐Yu Yang, Yi Li, Wen‐Long Ye, Feng Liu, Xiao‐Shun He, Jing‐Ru Wang, Wen‐Juan Gan, Xiu‐Ming Li, Shen Zhang, Yuan‐Yuan Zhao, Jian‐Ming Li – 3 June 2019 – The oncogene c‐Myc is aberrantly expressed and plays a key role in malignant transformation and progression of hepatocellular carcinoma (HCC). Here, we report that c‐Myc is significantly up‐regulated by tumor necrosis factor receptor–associated factor 6 (TRAF6), an E3 ubiquitin ligase, in hepatocarcinogenesis.

High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase–Lowering Effect of a HSD17B13 Variant

Helene Gellert‐Kristensen, Børge Grønne Nordestgaard, Anne Tybjærg‐Hansen, Stefan Stender – 3 June 2019 – A common loss‐of‐function variant in HSD17B13 (rs72613567:TA) was recently found to protect from chronic liver disease. Whether the variant confers protection from specific risk factors for liver disease is unclear. We tested the association of rs72613567 with plasma levels of alanine transaminase (ALT) and clinical liver disease and mortality in 111,612 individuals from the Danish general population, including 497 with cirrhosis and 113 with hepatocellular carcinoma.

Subscribe to